IP Library Granted Patent US 11,027,072
Granted Patent B2
US 11,027,072 · App. 16/592,319 · Granted Jun 8, 2021

Emergency devices

Inventors: Mark J. Flather (San Diego, CA); Karen K. Daniels (San Diego, CA); Thomas Moll (San Diego, CA); Ronald B. Moss (San Diego, CA); Dennis J. Carlo (San Diego, CA)
Assignee: Adamis Pharmaceuticals Corporation
A61M5/31535A61K31/485A61M5/31591
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,027,072
App. No.
16/592,319
Granted
Jun 8, 2021
Kind
B2
Abstract

Described herein are syringe devices comprising a syringe including a therapeutic dose of at least one drug to be used in a drug or substance overdose. Also provided herein are compositions and methods of treating opioid overdose using high dose naloxone.

Claims (18)

1. A high dose naloxone composition including naloxone at a dose greater than or equal to about 5 mg configured for administration, wherein C max is between 15 ng/mL to 24 ng/mL and the administration is an injection.

2. The high dose naloxone composition of claim 1 , wherein the dose is greater than about 10 mg.

3. The high dose naloxone composition of claim 1 , including naloxone hydrochloride at a dose of 5 mg/0.5 mL.

4. The high dose naloxone composition of claim 3 , wherein the composition is configured for a single administration.

5. The high dose naloxone composition of claim 4 , wherein the administration is using an injection device.

6. The high dose naloxone composition of claim 1 , wherein the composition is aqueous.

7. The high dose naloxone composition of claim 1 , wherein the C max is 15.8 ng/mL.

8. The high dose naloxone composition of claim 1 , wherein the C max is 17.2 ng/mL.

9. A high dose naloxone composition including naloxone at a dose greater than about 5 mg configured for administration, wherein the AUC 0-0.04 h is between 0.01 h*ng/mL and 0.1 h*ng/mL and the administration is an injection.

10. The high dose naloxone composition of claim 9 , including naloxone hydrochloride at a dose of 5 mg/0.5 mL.

11. The high dose naloxone composition of claim 10 , wherein the composition is configured for a single administration.

12. The high dose naloxone composition of claim 11 , wherein the administration is using an injection device.

13. The high dose naloxone composition of claim 9 , wherein the AUC 0-0.04 h is 0.0129 h*ng/mL.

14. A high dose naloxone composition including naloxone at a dose greater than or equal to about 5 mg configured for administration, wherein the AUC 0-0.08 h is between 0.05 h*ng/mL to 0.2 h*ng/mL and the administration is an injection.

15. The high dose naloxone composition of claim 14 , including naloxone hydrochloride at a dose of 5 mg/0.5 mL.

16. The high dose naloxone composition of claim 15 , wherein the composition is configured for a single administration.

17. The high dose naloxone composition of claim 16 , wherein the administration is using an injection device.

18. The high dose naloxone composition of claim 14 , wherein the AUC 0-0.08 h is 0.0782 h*ng/mL.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2024
From: DMK PHARMACEUTICAL CORPORATION
To: ZMI PHARMA INC.
Reel/Frame 068005/0373 →
CHANGE OF NAME Recorded Sep 28, 2023
From: ADAMIS PHARMACEUTICALS CORPORATION
To: DMK PHARMACEUTICALS CORPORATION
Reel/Frame 065082/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2019
From: FLATHER, MARK J.; DANIELS, KAREN K.; MOLL, THOMAS; MOSS, RONALD B.; CARLO, DENNIS J.
To: ADAMIS PHARMACEUTICALS CORPORATION
Reel/Frame 050859/0355 →
Continuity (4)
Continuation In Part 16422639 · May 24, 2019
Provisional Application 62676742 · May 25, 2018
Provisional Application 62747007 · Oct 17, 2018
Related Publication 20200121859A1 · Apr 23, 2020
Cited By (3)
US 12,194,263 US 12,285,581 US 12,350,473